Long-term retension of abatacept versus TNFi in patients with rheimatoid arthritis with first biological DMARD failure

Trial Profile

Long-term retension of abatacept versus TNFi in patients with rheimatoid arthritis with first biological DMARD failure

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Nov 2017 Results assessing the long-term retention of abatacept and TNF inhibitor (TNFi) following first biologic (b)DMARD inadequate response in RHUMADATA registry patients with RApresented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 06 Jul 2017 New trial record
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top